Overview

A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

Status:
Completed

Trial end date:
2020-06-24

Target enrollment:

Participant gender:

Summary

This is an open label study to evaluate the safety of ZX008 (fenfluramine) in patients with Dravet syndrome (DS) or Lennox Gastaut syndrome (LGS) who are being administered cannabidiol (CBD).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Treatments:

Cannabidiol
Fenfluramine